

# Hamim Zahir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3593351/publications.pdf>

Version: 2024-02-01

14  
papers

575  
citations

1162367

8  
h-index

1058022

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

753  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 480-492.	1.0	8
2	Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-glycoprotein. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 298-306.	1.0	8
3	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1422-1432.	1.3	7
4	Abuse potential of mirogabalin in recreational polydrug users. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861983603.	1.0	8
5	Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 112-121.	1.1	8
6	Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin. <i>Clinical Drug Investigation</i> , 2018, 38, 1001-1009.	1.1	10
7	Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2317-2324.	1.1	13
8	Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00418.	1.1	20
9	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 597-612.	0.8	8
10	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <i>Critical Care</i> , 2016, 20, 273.	2.5	19
11	Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate. <i>Circulation</i> , 2015, 131, 82-90.	1.6	240
12	Metabolism and disposition of [ <sup>14</sup> C]tivantinib after oral administration to humans, dogs and rats. <i>Xenobiotica</i> , 2014, 44, 996-1008.	0.5	11
13	Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 331-342.	1.0	179
14	Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. <i>Thrombosis and Haemostasis</i> , 2012, 108, 166-175.	1.8	36